PRNewsWire
23 Sept 2026, 13:46 UTC · 1h ago
Verdict
Headline takes no side. We score JNJ +1.00 across three claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 3 new · 0 priced in
Model-based analysis of the MajesTEC-3 study estimates that ~87% of patients treated with TECVAYLI plus DARZALEX FASPRO may experience a mortality risk and life expectancy similar to the general population.
Newpress release dated Sep 23, 2026
So whatA projected life expectancy of 18.5 years versus 4.9 years for SOC strengthens the case for moving these high-cost therapies into earlier lines of treatment, expanding the addressable patient population.
More positive than 99% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Post hoc analysis shows Tec-Dara reduced the risk of cumulative incidence of disease progression by 90% versus standard of care (SOC) at 36 months.
Newpress release dated Sep 23, 2026
So whatThe cumulative incidence of progression was only 8.7% for the combination compared to 62.1% for SOC, likely driving a higher long-term market share capture over competitors in the 1-3 prior line segment.
More positive than 92% of claims this week
The 36-month overall survival (OS) rate for patients on the combination therapy was 83.3% compared to 65.0% for those on SOC.
Newpress release dated Sep 23, 2026
So whatThe hazard ratio of 0.46 provides statistically significant evidence that supports premium pricing and reimbursement justifications for the combined regimen.
More positive than 77% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company announced highly positive Phase 3 study results showing significantly improved survival and disease control for its multiple myeloma therapies.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Accesswire
4h ago
The Motley Fool
10h ago
+1.0%
Price agrees with the score
$271.92 vs $269.19 close before publication (Sep 22) · not market-adjusted
JNJ chart →
